GSK plc (LON:GSK) Insider Emma Walmsley Acquires 8 Shares

GSK plc (LON:GSKGet Free Report) insider Emma Walmsley bought 8 shares of GSK stock in a transaction on Friday, February 9th. The shares were purchased at an average cost of GBX 1,662 ($20.99) per share, with a total value of £132.96 ($167.92).

GSK Price Performance

Shares of GSK opened at GBX 1,626.40 ($20.54) on Tuesday. GSK plc has a twelve month low of GBX 1,302.60 ($16.45) and a twelve month high of GBX 1,674.40 ($21.15). The stock’s 50 day moving average is GBX 1,523.19 and its two-hundred day moving average is GBX 1,464.01. The firm has a market capitalization of £66.03 billion, a PE ratio of 1,355.33, a P/E/G ratio of 1.29 and a beta of 0.26. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82.

GSK Increases Dividend

The business also recently declared a dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, February 22nd will be given a dividend of GBX 16 ($0.20) per share. This represents a dividend yield of 1.04%. This is an increase from GSK’s previous dividend of $14.00. The ex-dividend date is Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is presently 5,333.33%.

Analyst Ratings Changes

A number of analysts have weighed in on GSK shares. Barclays restated a “buy” rating and issued a GBX 1,950 ($24.63) price target on shares of GSK in a research note on Friday. Shore Capital reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, January 31st. Citigroup reissued a “neutral” rating on shares of GSK in a report on Tuesday, November 28th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 1,650 ($20.84) price target on shares of GSK in a report on Friday, November 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of GBX 1,650 ($20.84).

View Our Latest Stock Report on GSK

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading

Insider Buying and Selling by Quarter for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.